



Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory *NPM1-m* or *KMT2A-r* Acute Myeloid Leukemia at 2025 ASH Annual Meeting

- *Data to be featured in two oral presentations on December 8, 2025 –*
- *Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use –*

SAN DIEGO and TOKYO, November 3 and 4, 2025 – Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced that results from the KOMET-007 combination trial of ziftomenib, a once-daily, oral investigational menin inhibitor, will be featured in two oral presentations at the upcoming American Society of Hematology (ASH) 2025 Annual Meeting, on December 8, 2025 in Orlando, FL.

KOMET-007 is an ongoing Phase 1a/b dose-escalation/expansion study of ziftomenib in combination with standard-of-care chemotherapies in adults with *NPM1*-mutated (*NPM1-m*) or *KMT2A*-rearranged (*KMT2A-r*) acute myeloid leukemia (AML). The combination data presented at ASH will include data in both newly diagnosed adults with *NPM1-m* AML and updated data in adults with relapsed or refractory *NPM1-m* or *KMT2A-r* AML treated with ziftomenib in combination with the non-intensive chemotherapy regimen of venetoclax and azacitidine (ven/aza).

The two ziftomenib abstracts are based on an earlier data cutoff of June 2025, in line with ASH submission timelines. The oral presentations at ASH will include more mature data, including additional response-evaluable patients, longer follow-up and expanded safety summaries.

“At ASH 2025, we look forward to sharing data evaluating ziftomenib with venetoclax / azacitidine in both the newly diagnosed and relapsed/refractory AML settings,” said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. “These trials are part of a comprehensive and focused clinical development plan designed to understand how menin inhibition can benefit the greatest number of patients in need. We expect to continue generating data from the combination of ziftomenib with commonly used

treatment backbones across multiple trials, including the KOMET-017 Phase 3 trial. The emerging profile from this effort gives us confidence that ziftomenib as monotherapy and in combination represents a meaningful step forward for patients if these findings are confirmed.”

ASH Presentations:

Ziftomenib in Combination with Venetoclax and Azacitidine in Relapsed / Refractory *NPM1*-m or *KMT2A*-r Acute Myeloid Leukemia: Updated Phase 1a/b safety and clinical activity results from KOMET-007

Session 616. Menin inhibitors and FLT3 inhibitors in AML

Monday, December 8, 2025; 10:45-11:00 AM ET

Chapin Theater (320)

Oral #764

Ziftomenib in Combination with Venetoclax and Azacitidine in Newly Diagnosed *NPM1*-m Acute Myeloid Leukemia: Phase 1b Results from KOMET-007

Session 616. Menin inhibitors and FLT3 inhibitors in AML

Monday, December 8, 2025; 11:15-11:30 AM ET

Chapin Theater (320)

Oral #766

Copies of the presentations will be available on Kura's website at www.kuraoncology.com/pipeline/publications/ following presentation at the meeting.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at <https://kuraoncology.com/> and follow us on [X](#) and [LinkedIn](#).

About Kyowa Kirin

Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, Kyowa Kirin has invested in drug discovery and biotechnology innovation for more than 70 years and is currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hematology and rare diseases. A shared commitment to Kyowa Kirin's values, to sustainable growth, and to making people smile unites Kyowa Kirin across the globe. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.